ROSGQ — Rosetta Genomics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Rosetta Genomics announces receipt of conditional approval
Brief: Rosetta Genomics Q1 non-gaap loss per share $0.18 excluding items
Brief: Rosetta Genomics files for mixed shelf of up to $75 mln
Brief: Rosetta Genomics and Biocept advance collaboration to proof-of-concept studies aimed at microrna profiling of circulating tumor cells to enhance lung cancer diagnosis
Brief: Rosetta Genomics Q3 loss per share $0.27
Brief: Rosetta Genomics raises $8,000,000 in private placement
Brief: Rosetta affirms 2015 pro forma full-year revenue guidance of $10 mln to $12 mln
Brief: Rosetta Genomics says agreement with MultiPlan
Brief: Rosetta Genomics' patent on therapeutic use of mir-34a upheld by European patent office in opposition proceedings
Brief: Rosetta Genomics receives U.S. patent for cancer of origin diagnostic assay
Brief: Rosetta Genomics to acquire PersonalizeDX
Brief: Rosetta Genomics says plans to introduce oncogxone, Admera Health's NGS panel
Brief: Rosetta Genomics says on track to launch novel thyroid cancer assay by Q3 end
Brief: Rosetta Genomics reports commercial partnership with Precipio Diagnostics
Brief: Rosetta Genomics says expect revenue for the second half 2014 to be 40 pct higher vs first half
Brief: Rosetta Genomics and Marina Biotech start first clinical project under strategic alliance
Brief: Biocept and Rosetta Genomics collaborate to evaluate microRNAs from circulating tumor cells
Market Pulse: Alnylam, Intercept, Clicksoftware, NII Holdings, Juniper
Market Pulse: Alnylam, Intercept, Clicksoftware, NII Holdings, Juniper